Guangshengtang: The anti-new coronavirus small molecule oral innovative drug project is still in the preclinical research stage

Shanghai Securities News China Securities Network News (reporter Luo Min) Guangshengtang disclosed that the company's holding subsidiary Fujian Guangsheng Zhonglin Biotechnology Co., Ltd. anti-novel coronavirus small molecule oral innovative drug project is still in the pre-clinical research stage, follow-up also need to be through the compound property characterization research to determine preclinical candidate compounds (PCC), complete preclinical pharmacy research and in line with the clinical registration declaration of pharmacokinetics, pharmacodynamics, pharmacology and toxicology research, And after obtaining the clinical (implied) license of the State Drug Administration (NMPA), phase I, II and PHASE III clinical studies are carried out, and only after obtaining the corresponding safety and efficacy data can the drug registration application be submitted to the NMPA, and the drug registration certificate is obtained through the NMPA review and approval and the good manufacturing practice (GMP) compliance inspection of the API, the project product can be produced and sold.